AcouSort announces preliminary outcome of rights issue
AcouSort AB (publ) ("AcouSort" or the “Company") today announces the preliminary outcome of the rights issue of units, consisting of shares and warrants of series TO2, which was announced on 7 November 2023 (the “Rights Issue”). The preliminary outcome is that the Rights Issue has been subscribed to a total of approximately 93.4 percent, of which approximately 70.8 percent were subscribed with unit rights, approximately 22.6 percent were subscribed without unit rights. Through the Rights Issue, AcouSort is expected to receive approximately MSEK 23.2 before issuing costs.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, UNITED KINGDOM, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS WHOLLY OR PARTIALLY SUBJECT TO LEGAL RESTRICTIONS. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW.
The subscription period in the Rights Issue ended on 30 November 2023, and the preliminary results show that 390,800 units, equivalent to approximately 70.8 percent of the Rights Issue, were subscribed for through the support of unit rights. In addition, 124,726 units were subscribed for without the support of unit rights, equivalent to approximately 22.6 percent of the Rights Issue. Upon full exercise of all issued warrants of series TO2, the Company may additionally receive at most MSEK 10.8 before issuing costs.
Those who have subscribed for units without the support of unit rights will be allocated units according to the principles set out in the information memorandum published by the Company on 14 November 2023. The subscribed and allocated units must be paid in cash according to the instructions on the settlement note. Shareholders registered with a nominee will be notified of their allocation in accordance with the nominee's procedures. Each unit consists of three (3) shares and (1) warrant of series TO 2. The final outcome of the Rights Issue is expected to be announced around 4 December 2023.
Through the Rights Issue, the share capital in the Company increases by SEK 154,657.80, from SEK 1,324,796.40 to SEK 1,479,454.20, and the number of shares increases by 1,546,578 shares, from 13,247,964 shares to 14,794,542 shares, corresponding to a dilution effect of approximately 10.5 percent. Upon full exercise of all issued warrants of series TO2, the share capital will increase by an additional SEK 51,552.60 and the number of shares by an additional 515,526 shares, corresponding to a dilution effect of approximately 3,4 percent.
Advisors
Penser By Carnegie, Carnegie Investment Bank AB (publ) is the financial advisor and issuing agent and Fredersen Advokatbyrå AB is legal advisor to AcouSort in connection with the Rights Issue.
This is information of the type that AcouSort AB (publ) is obligated to make public in accordance with the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person above on 2023-11-30 7:00 pm CET.
FOR FURTHER INFORMATION, PLEASE CONTACT
Torsten Freltoft, CEO
AcouSort AB
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
ABOUT ACOUSORT AB
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Carnegie Investment Bank AB (publ).
IMPORTANT INFORMATION
The information in this press release does not constitute an offer to acquire, subscribe or otherwise trade in units, unit rights or other securities in AcouSort. The invitation to concerned persons to subscribe for units in AcouSort has only been made through the information memorandum published by AcouSort on 14 November 2023. No action has been taken, or will be taken, by AcouSort to permit an offer to the public in jurisdictions other than Sweden.
This press release may not be published or distributed, directly or indirectly, in or to Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, United Kingdom, the United States or any other jurisdiction where such action in whole or in part is subject to legal restrictions, or would require additional prospectus, registration or other measures than what follows from Swedish law. The information in this press release may also not be forwarded or reproduced in a way that is contrary to such restrictions or would entail such requirements. Actions contrary to this instruction may constitute a violation of applicable securities legislation. No securities mentioned in this press release have been registered or will be registered under the United States Securities Act of 1933 as amended (the "Securities Act") and may not be offered, subscribed for, exercised, pledged, sold, resold, delivered or transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from the registration requirements of the Securities Act. The offer is also not directed at persons domiciled in Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, United Kingdom or in any other jurisdiction where participation would require additional prospectus, registration or other measures than those that follow from Swedish law.
FORWARD-LOOKING STATEMENTS
This press release contains certain forward-looking statements that reflect AcouSorts’ current views and expectations regarding future events and financial and operational developments, including statements regarding the Rights Issue and statements regarding guidance, planning, prospects and strategies. Words such as "intended," "estimated," "expected," "planned," "estimated," "may," and other expressions that imply indications or predictions of future developments or trends and are not based on historical facts constitute forward-looking statements information. Although AcouSort believes that these statements are based on reasonable assumptions and expectations, AcouSort cannot guarantee that such forward-looking statements will be realized. Because these forward-looking statements involve both known and unknown risks and uncertainties, actual outcomes may differ materially from those expressed in forward-looking information. Forward-looking statements in the press release speak only as of the date of the press release and are subject to change without notice. Potential investors should not place undue reliance on the forward-looking information contained herein, and potential investors are strongly encouraged to read those parts of the prospectus that include a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The Company makes no promises to publish updates or revisions to forward-looking statements as a result of new information, future events or the like beyond what is required by applicable laws or stock market regulation.